Nyxoah price target raised to $20 from $10 at Stifel

Stifel analyst Jonathan Block raised the firm’s price target on Nyxoah to $20 from $10 and keeps a Buy rating on the shares. Given the firm’s expectation that Nyxoah releases top-line DREAM data next month, the firm surveyed ear, nose and throat doctors to see how market share between Nyxoah and Inspire may shake out under different scenarios. Both scenarios the firm laid out to surveyed ENT doctors yield share above its prior estimates, and it also identified a “pre-existing” opportunity for Genio consisting of qualified HGNS candidates previously averse to undergoing Inspire Medical HGNS therapy, the analyst tells investors.